Novel scaled average bioequivalence limits based on GMR and variability considerations.
about
Evaluation of a scaling approach for the bioequivalence of highly variable drugs.Novel methods to assess bioequivalence.Current regulatory approaches of bioequivalence testing.Innovative approaches for demonstration of bioequivalence: the US FDA perspective.Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.
P2860
Novel scaled average bioequivalence limits based on GMR and variability considerations.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Novel scaled average bioequivalence limits based on GMR and variability considerations.
@en
Novel scaled average bioequivalence limits based on GMR and variability considerations.
@nl
type
label
Novel scaled average bioequivalence limits based on GMR and variability considerations.
@en
Novel scaled average bioequivalence limits based on GMR and variability considerations.
@nl
prefLabel
Novel scaled average bioequivalence limits based on GMR and variability considerations.
@en
Novel scaled average bioequivalence limits based on GMR and variability considerations.
@nl
P1476
Novel scaled average bioequivalence limits based on GMR and variability considerations.
@en
P2093
Mira Symillides
Panos Macheras
P304
P356
10.1023/B:PHAM.0000045249.83899.AE
P577
2004-10-01T00:00:00Z